Search Results - "Reckova, M"

An ongoing evolution of cardio-oncology with the rapid development of modern immunotherapy by Reckova, M., Mladosievicova, B.

Get full text

Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial by Mego, M, Svetlovska, D, Angelis V, De, Kalavska, K, Lesko, P, Makovník, M, Obertova, J, Orszaghova, Z, Palacka, P, Rečková, M, Rejlekova, K, Z, Sycova-Mila, Mardiak, J, Chovanec, M

“…Background Multiple relapsed/refractory germ cell tumor (GCT) patients have extremely poor prognosis. Cisplatin resistant testicular GCTs overexpress…”
Get full text

Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial by Mego, M., Svetlovska, D., Reckova, M., Angelis, De, Kalavska, K., Obertova, J., Palacka, P., Rejlekova, K., Sycova-Mila, Z., Chovanec, M., Mardiak, J.

“…Summary Background  Patients with multiple relapsed/refractory germ cell tumours (GCTs) have an extremely poor prognosis. PARP (poly-ADP-ribose polymerase) is…”
Get full text

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases by Loriot, Y., Pagliaro, L., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.C., Malhaire, J.P., Linassier, C., Habibian, M., Martin, A.L., Journeau, F., Reckova, M., Logothetis, C., Laplanche, A., Le Teuff, G., Culine, S., Fizazi, K.

“…The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and…”
Get full text

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma by Mego, M., Reckova, M., Obertova, J., Sycova-Mila, Z., Brozmanova, K., Mardiak, J.

Get full text

Treatment of hemodialyzed patient with sunitinib by Reckova, M., Kakalejcik, M., Beniak, J.

Get full text

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer by Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., Mardiak, J.

“…Summary Background Germ cell tumors (GCTs) are highly curable diseases; however, not all patients can be cured. Patients in their second relapse have…”
Get full text

Differences in Incidence and Biological Characteristics of Breast Cancer between Roma and Non-Roma Patients in Slovakia by Reckova, M, Mardiak, J, Plank, L, Vulevova, M, Cingelová, S, Mego, M

“…Roma (Gypsies) constitute one of the largest ethnic minorities in Slovakia. Some reports have supported a higher prevalence of communicable diseases in Roma…”
Get more information

Differences in Age-distribution, Oncological Diagnoses and Stage in Roma and Non-Roma Cancer Patients Registered at the Outpatient Oncology Department Poprad in 2014 and 2015 - a Retrospective Study by Reckova, M, Mardiak, J, Beniak, J, Kakalejcik, M, Medvecova, L, Cingelová, S, Mego, M

“…Roma (Gypsies) constitute the largest ethnic minority in Slovakia. Although some studies have reported a higher prevalence of communicable diseases in Roma,…”
Get more information

Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Hlavatá, Z, Mego, M, Recková, M, Koza, I

“…The aim of this study was to determine efficacy and toxicity of TIP combination (paclitaxel, ifosfamid, cisplatin) as first salvage treatment in patients with…”
Get more information

PCN58 Metastatic Renal Carcinoma Costs in Slovakia: Analysis of Direct and Indirect Costs in 2018 by Babela, R., Reckova, M., Mego, M.

Get full text

Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors by Mego, M, Rejlekova, K, Reckova, M, Sycova-Mila, Z, Obertova, J, Rajec, J, Mardiak, J

“…Early serum tumor marker decline (STMD) during chemotherapy was shown to predict survival in patients with poor prognosis non-seminomatous germ cell tumors…”
Get more information

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Recková, M, Mego, M, Hlavatá, Z, Brozmanová, K, Risnyovzská, Z, Svetlovská, D, Koza, I

“…First line treatment of patients pts with poor-prognosis GCT, using BEP, is unsatisfactory. T-BEP (paclitaxel followed by BEP) demonstrated promising efficacy…”
Get more information

Small-cell carcinoma of the ovary with breast metastases: a case report by Reckova, M, Mego, M, Rejlekova, K, Sycova-Mila, Z, Obertova, Z, Mardiak, J

“…Small cell carcinoma (SCC) is characterised by high metastatic potential and the possibility to metastasize to practically any tissue. Small cell carcinoma of…”
Get more information

Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study by Mardiak, J, Sálek, T, Sycová-Milá, Z, Obertová, J, Hlavatá, Z, Mego, M, Recková, M, Koza, I

“…The aim of the study was to determine the efficacy and toxicity of gemcitabine, cisplatin and paclitaxel (GCP) combination as a first salvage treatment of…”
Get more information

Bevacizumab in a growing teratoma syndrome. Case report by Mego, M, Recková, M, Syčova-Mila, Z, Obertova, J, Brozmanova, K, Salek, T, Mardiak, J

Get full text

Differences in incidence and biological characteristics between Roma and non-Roma women with breast cancer in Slovakia by Reckova, M., Mardiak, J., Plank, L., Vulevova, M., Cingelova, S., Mego, M.

Get full text

713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial by Naoun, N., Le Teuff, G., Pagliaro, L., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C.M., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J-C., Malhaire, J.P., Linassier, C., Reckova, M., Nenan, S., Culine, S., Fizazi, K.

Get full text

Functional and morphological evidence for a ventricular conduction system in zebrafish and Xenopus hearts by Sedmera, David, Reckova, Maria, deAlmeida, Angela, Sedmerova, Martina, Biermann, Martin, Volejnik, Jiri, Sarre, Alexandre, Raddatz, Eric, McCarthy, Robert A, Gourdie, Robert G, Thompson, Robert P

“…Zebrafish and Xenopus have become popular model organisms for studying vertebrate development of many organ systems, including the heart. However, it is not…”
Get more information

Hemodynamics Is a Key Epigenetic Factor in Development of the Cardiac Conduction System by Reckova, Maria, Rosengarten, Carlin, deAlmeida, Angela, Stanley, Chiffvon P, Wessels, Andy, Gourdie, Robert G, Thompson, Robert P, Sedmera, David

“…ABSTRACT—The His-Purkinje system (HPS) is a network of conduction cells responsible for coordinating the contraction of the ventricles. Earlier studies using…”
Get full text